A Novel Osteoblast-derived C-type Lectin That Inhibits Osteoclast Formation*

Hong Zhou, Vicky Kartsogiannis, Yun Shan Hu, Jan Elliott, Julian M. W. Quinn, William J. McKinstry, Matthew T. Gillespie, and Kong Wah NgDagger

From the Department of Medicine, University of Melbourne, St. Vincent's Hospital, and St. Vincent's Institute of Medical Research, Fitzroy, Victoria 3065, Australia

Received for publication, December 21, 2000, and in revised form, February 6, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have cloned and expressed murine osteoclast inhibitory lectin (mOCIL), a 207-amino acid type II transmembrane C-type lectin. In osteoclast formation assays of primary murine calvarial osteoblasts with bone marrow cells, antisense oligonucleotides for mOCIL increased tartrate-resistant acid phosphatase-positive mononucleate cell formation by 3-5-fold, whereas control oligonucleotides had no effect. The extracellular domain of mOCIL, expressed as a recombinant protein in Escherichia coli, dose-dependently inhibited multinucleate osteoclast formation in murine osteoblast and spleen cell co-cultures as well as in spleen cell cultures treated with RANKL and macrophage colony-stimulating factor. Furthermore, mOCIL acted directly on macrophage/monocyte cells as evidenced by its inhibitory action on adherent spleen cell cultures, which were depleted of stromal and lymphocytic cells. mOCIL completely inhibited osteoclast formation during the proliferative phase of osteoclast formation and resulted in 70% inhibition during the differentiation phase. Osteoblast OCIL mRNA expression was enhanced by parathyroid hormone, calcitriol, interleukin-1alpha and -11, and retinoic acid. In rodent tissues, Northern blotting, in situ hybridization, and immunohistochemistry demonstrated OCIL expression in osteoblasts and chondrocytes as well as in a variety of extraskeletal tissues. The overlapping tissue distribution of OCIL mRNA and protein with that of RANKL strongly suggests an interaction between these molecules in the skeleton and in extraskeletal tissues.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The interactions of the recently discovered proteins RANKL (Receptor Activator of NF-kappa B ligand), osteoprotegerin (OPG),1 and RANK, the cognate receptor for RANKL, along with M-CSF are crucial to the formation of osteoclasts. Osteoclasts, multinucleate cells responsible for bone resorption, are derived from hematopoietic stem cells that differentiate along the macrophage/monocyte lineage (1, 2). Direct contact between osteoblasts or stromal cells with mononuclear precursors of osteoclasts is required for their differentiation into mature, functional, multinucleate osteoclasts (3). Osteoblasts/stromal cells express a membrane-bound protein termed RANKL, which stimulates the differentiation and formation of multinucleate osteoclasts from mononuclear precursors when it binds to its receptor, RANK (4). RANKL is also known as TRANCE (5, 6) ODF (7), or OPGL (8, 9). Recombinant protein corresponding to the extracellular domain of RANKL stimulates the formation of active, bone-resorbing osteoclasts from hematopoietic cells derived from spleen even in the absence of stromal cells (10). RANKL expression is stimulated by bone-resorbing factors such as parathyroid hormone, PGE2, 1,25-dihydroxyvitamin D3, and interleukin-1beta and -11 (7, 11, 12). In addition to the stimulation of osteoclast differentiation, RANKL also enhances the activity of mature osteoclasts (13), inhibits osteoclast apoptosis (14), and enhances osteoclast survival (15).

OPG is a soluble member of the tumor necrosis factor receptor family that is secreted by osteoblastic stromal cells. It acts as a decoy receptor for RANKL, antagonizing its biological actions by preventing it from binding to and activating its receptor, RANK (16). Overexpression of OPG in transgenic mice results in severe osteopetrosis, with impaired formation of marrow cavity and profound depletion of osteoclasts. Furthermore, OPG blocks ovariectomy-associated bone loss in the rat. In addition to inhibition of osteoclast formation, OPG also inhibits resorption pit formation by mature osteoclasts and antagonizes the induction of bone resorption by 1,25-dihydroxyvitamin D3, parathyroid hormone, PGE2, and IL-1alpha as well as RANKL (14, 17-19). Other inhibitors of osteoclast formation have been identified in recent years. They include IL-4, IL-10, IL-18, interferon-gamma , and GM-CSF (20, 21) as well as legumain and Sca, which were cloned and isolated from a human osteoclast cDNA expression library. Legumain (22) is a member of the mammalian cysteine protease family, the asparaginyl endopeptidases (23), whereas Sca is a glycosylphosphatidylinositol-linked osteoclast inhibitory factor (24).

In pursuit of a factor that regulates the formation of osteoclasts, we have identified an osteoblast-derived membrane protein with structural homology to the C-type lectin family that limits osteoclast formation. The full-length cDNA of osteoclast inhibitory lectin (OCIL) predicts OCIL to be a 207-amino acid type II membrane protein with a 143-amino acid extracellular domain, a 21-amino acid transmembrane domain, and a 43-amino acid cytoplasmic domain.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Rat UMR 201 cells, rat UMR 106 cells, and primary mouse calvarial osteoblasts were routinely grown in alpha -minimal essential medium containing 10% fetal bovine serum. Incubation was carried out at 37 °C in a humidified atmosphere equilibrated with 5% CO2 in air. Dr. S. Rodan (Merck Research Laboratories, West Point, PA) generously provided a rat ROS 17/2.8 cDNA library. M-CSF was a gift from Genetics Institute (Cambridge, MA). Recombinant murine RANKL was obtained from Preprotech Inc. (Canton, MA). [alpha -32P]dCTP was purchased from PerkinElmer Life Sciences. All other reagents were of analytic grade and were obtained from standard suppliers. The mouse cDNA library was purchased from Stratagene (La Jolla, CA).

cDNA Cloning from Rat and Mouse cDNA Libraries-- We hypothesized that mature osteoblasts might express osteoclastogenic inhibitors, based on the observation that mature osteoblasts have limited potential to support osteoclast formation (11). The preosteoblastic cell line UMR 201 was differentiated with 1 µM retinoic acid to enable the expression of a more mature osteoblast phenotype (25, 26), and mRNA profiles were compared between untreated and retinoic acid-treated cells by differential display-polymerase chain reaction as previously described (27).

Briefly, total RNA was isolated from untreated and retinoic acid-treated preosteoblastic UMR 201 cells using guanidine thiocyanate (28). First strand cDNA was synthesized from 2 µg of total RNA by incubation for 1 h at 42 °C with 15 units of avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI) following T12VA, T12VC, or T12VG priming. The primers used in the PCR were 5'-ATG CTG GGC ACG TAC ACA CAA-3' and either T12VA, T12VC, or T12VG (CLONTECH, CA). The PCR conditions utilized a touchup PCR protocol with denaturation at 94 °C for 5 min and then five cycles of 94 °C for 1 min, 37 °C for 1 min, and 72 °C for 1 min, followed by 35 cycles of 94 °C 1 min, 49 °C for 1 min, and 72 °C for 1 min. For these experiments, the Expand High Fidelity PCR system (Roche Molecular Biochemicals, Mannheim, Germany) was used in a PerkinElmer Life Sciences 480 thermal cycler. A 321-bp PCR product was obtained. To extend its sequence, anchored PCR was used to screen a rat ROS 17/2.8 cDNA library with lambda gt11 arms. A 25-bp antisense primer that was complementary to a sequence in the 321-bp fragment, 5'-TGA GTG TTG TCT GTC CAC TTC CAA G-3', was used with either the lambda gt11 forward primer (5'-GGT GGC GAC GAC TCC TGG AGC C-3') or the lambda gt11 reverse primer (5'-GAC ACC AGA CCA ACT GGT AAT G-3') (CLONTECH) to amplify further nucleotide sequences. Cycling parameters were 94 °C for 5 min and then 80 cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 2 min, followed by a final extension step of 72 °C for 10 min. A 402-bp fragment, designated rOCIL402, was obtained with the lambda gt11 reverse primer as the anchored primer. The 402-bp fragment was labeled with [alpha -32P]dCTP using a random primer labeling kit (Roche Molecular Biochemicals) to screen a mouse liver cDNA library at 65 °C in hybridization buffer containing 4× SSPE (SSPE = 0.15 M NaCl, 0.01 M NaH2PO4, and 0.001 M EDTA), 5× Denhardt's solution, and 0.5% SDS for 24 h. The filters were then washed sequentially in 2× SSC at 65 °C for 15 min, 2× SSC with 0.1% SDS at 65 °C for 30 min, and finally 0.1× SSC at 65 °C for 10 min. A 1206-bp cDNA termed mOCIL was obtained.

The full-length rat OCIL cDNA was obtained from total RNA isolated from human parathyroid hormone-(1-34)-treated rat osteoblast-like UMR 106 cells. A 3'-rapid amplification of cDNA ends strategy was used to obtain the 3'-end of rat OCIL using the 3'-adaptor primer 5'-GGC CAC GCG TCG ACT AGT ACT TTT TTT TTT TTT TTT T-3' (CLONTECH) for the reverse transcription, followed by amplification with universal adaptor primer 5'-GGC CAC GCG TCG ACT AGT-3' and the sense primer 5'-GAA ACA TCC CCC TGG AGT ATC C-3', which was complementary to sequences within rOCIL402. A 5'-rapid amplification of cDNA ends strategy was used to obtain the 5'-ends of the rat OCIL cDNA using the SMART RACE cDNA amplification kit (CLONTECH). The antisense primer 5'-CTC AGT GTT GTC TGT CCA CTT CCA AGG G-3' was complementary to sequences within rOCIL402. The full-length rat OCIL cDNA sequence is 1628 bp.

Osteoclast Formation Assays-- Osteoclast formation was assessed either by culturing mouse bone marrow cells with calvarial osteoblasts or by culturing mouse spleen cells with soluble RANKL and M-CSF.

Mouse bone marrow cell cultures were prepared as described previously (29, 30). Bone marrow cells from long bones of 6-9-week-old male C57BL/6J mice were co-cultured with calvarial osteoblasts obtained from newborn mice in the absence or presence of 10 nM 1,25-dihydroxyvitamin D3 and 10 nM PGE2. The expression of mOCIL was inhibited by concurrently treating the co-cultures with antisense oligonucleotides added with medium changes on days 0 and 3 of a 7-day co-culture. The following phosphorothioate oligodeoxynucleotides for mOCIL were used at 5 µM with the co-cultures: 5'-GAG TGT TGT CTG TCC ACT TCC-3', complementary to the extracellular domain, and 5'-GGT AGG GAA GCC TTT GTG AC-3', complementary to the intracellular domain. Scrambled phosphorothioate oligonucleotides with the same base composition as the antisense oligonucleotides were used as controls for these experiments: 5'-CGC TCG CTG TAT GTC TGC TAT-3' for the extracellular domain and 5'-AGT CGT GCG TAG TGC GAG TA-3' for the intracellular domain. After 7 days, cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP) using an acid phosphatase leukocyte commercial kit (Sigma). TRAP-positive multinucleate cells were further characterized as osteoclasts by the presence of calcitonin receptors, demonstrated by immunohistochemistry (30).

Mouse spleen cells were obtained from adult mice and cultured for 7 days in culture medium containing 10% fetal bovine serum, 25 ng/ml M-CSF, and 50 ng/ml soluble RANKL in the absence or presence of maltose-binding protein (MBP) vector control or recombinant MBP-mOCIL fusion protein at various concentrations. To obtain cultures of adherent spleen cells that were depleted of non-adherent erythrocytes and lymphocytes, spleen cell suspensions were added to 10-mm diameter culture wells (2 × 106 cells/well) containing 6-mm diameter glass coverslips. The cells were allowed to settle and attach for 40-60 min at 37 °C before the coverslips were removed and rinsed vigorously in alpha -minimal essential medium containing 10% fetal bovine serum. Coverslips were then placed on fresh 10-mm diameter wells containing 200 µl of alpha -minimal essential medium and 10% fetal bovine serum. Treatments were added on day 0 and with the medium change on day 3.

Expression of Recombinant mOCIL-- A DNA fragment encoding the extracellular domain (residues 76-207) of mOCIL was obtained by PCR and cloned into the EcoRI and HindIII sites of pMAL-c2 (New England Biolabs Inc., Beverly, MA), creating a gene fusion with the MBP-encoding malE gene. PCR was performed using mOCIL cDNA as a template. The reaction used a sense primer representing nucleotides 285-303 of mOCIL, encoding amino acids 76-81 (TYAACP), with an EcoRI site (5'-TCA GAA TTC ACC TAT GCT GCT TGC CCG C-3') and an antisense primer representing nucleotides 711 to 690 of mOCIL after the termination codon with a HindIII site (5'-GGT TAA GCT TCA GGC TAA AAA GCG TCT CTT GG-3'). The PCR product was digested with EcoRI and HindIII and cloned into pMAL-c2. E. coli BL21 cells were transformed with this construct, and the fusion protein was induced with 0.3 mM isopropyl-1-thio-beta -D-galactopyranoside for 3 h at 37 °C. The MBP-OCIL fusion protein was isolated from the soluble bacterial fraction by affinity chromatography as outlined in the manufacturer's instructions. The eluant fractions were subjected to SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Roche Molecular Biochemicals). Western blot analyses were performed with a rabbit anti-MBP serum (New England Biolabs Inc.) and a Boehringer Mannheim chemiluminescence blotting substrate peroxidase detection system (Roche Molecular Biochemicals). Fractions containing the MBP-OCIL fusion protein were pooled and concentrated using an Amicon ultrafiltration YM-10 membrane (Millipore, Bedford, MA). The protein concentration was measured in a BCA protein assay (Pierce).

Northern Blots-- UMR 106 osteoblast-like cells and primary mouse calvarial osteoblasts were treated for 24 h with osteotropic factors: retinoic acid, parathyroid hormone-(1-34), IL-1alpha , IL-1beta , IL-11, dexamethasone, and 1,25-dihydroxyvitamin D3. Total RNA was isolated, separated on a formaldehyde-containing 1.5% agarose gel, and transferred to nylon filters. Filters (GeneScreen, PerkinElmer Life Sciences) were hybridized with a digoxigenin-labeled mOCIL riboprobe overnight, and specifically bound probe was visualized by autoradiography after detection with anti-digoxigenin antibody as described previously (31). Relative mRNA levels were normalized for loading variability by comparison with 18 S rRNA levels in the same filters.

A 713-bp mOCIL riboprobe was generated by reverse transcription PCR using RNA derived from mouse calvarial osteoblasts with primers mOCIL-17 (5'-TGG AAA CTC AGC TCC TCA GCT CTG-3', representing nucleotides 34-57) and mOCIL-12 (5'-GGG ACC ATA GGG GAA AGA GTA G-3', representing nucleotides 725-746) and cloned into pGEM-T (Promega, Madison, WI). The plasmid was linearized with ApaI or PstI and transcribed with T7 or SP6 RNA polymerase to generate antisense and sense riboprobes, respectively. The riboprobes were labeled with digoxigenin during RNA transcription using a RNA labeling kit (Roche Molecular Biochemicals) according to the manufacturer's instructions.

Expression of OCIL mRNA during Osteoclast Formation-- OCIL mRNA expression during osteoclast formation in mouse bone marrow cultures was investigated by reverse transcription-PCR. Mouse bone marrow cells were cultured for 10 days in the presence of 10 nM 1,25-dihydroxyvitamin D3 as described (32). Total RNA was isolated at each 24-h time point. Reverse transcriptase-PCR was carried out using mOCIL-17 and mOCIL-12 as the sense and antisense primers, respectively. The PCR was run at 94 °C for 5 min and then for 30 cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 1 min, followed by a final extension step of 72 °C for 10 min. Southern blot analysis was carried out as reported (33). 20 µl of each PCR mixture was run on a 2% agarose gel and transferred to nylon membranes, and products were authenticated by probing with an internal antisense strand oligonucleotide complementary to mOCIL, labeled with digoxigenin-dUTP using a 3'-tailing kit (Roche Molecular Biochemicals). Hybridization was carried out with 2 pmol/ml labeled oligonucleotides in buffer containing 5× SSC, 0.02% SDS, 0.1% sarcosine, and 100 ng/ml poly(A) at 55 °C for 14 h. Detection was by chemiluminescence using CDP (Roche Molecular Biochemicals) according to the manufacturer's instructions.

The time course of OCIL mRNA expression during osteoclast formation was compared with mRNA expression of OPG. A set of sense and antisense primers were used as reported (11) with nucleotide sequences represented by OPG-7 (5'-TGA GTG TGA GGA AGG GCG TTA C-3', nucleotides 405-426) and OPG-3 (5'-TTT CTC GTT CTC TCA ATC TC-3', nucleotides 1021-1040), respectively. The PCR was run at 94 °C for 5 min and then for 35 cycles of 94 °C for 30 s, 57 °C for 30 s, and 72 °C for 1 min, followed by a final extension step of 72 °C for 10 min. Hybridization was carried out using the digoxigenin-labeled internal sense strand oligonucleotide OPG-1 (5'-ACC AAA GTG AAT GCC GAG-3') under the same conditions described above. To ensure equal starting quantities of RNA in each sample, the reverse-transcribed material was also amplified using oligonucleotide primers specific for rat GAPDH as described (33).

Tissue Distribution of OCIL Using Northern Blot Analysis-- Total RNA was extracted from adult mouse tissues for the detection of OCIL mRNA expression using Northern blot analysis as described above. Relative mRNA levels were normalized for loading variability by comparison with 18 S rRNA levels in the same filters.

In Situ Hybridization and Immunohistochemistry-- Skeletal and extraskeletal tissues were obtained from C57BL/6J male mice. Long bones from the femurs and tibiae of embryo (15 days of gestation), newborn (days 1, 3, and 7), and adult (week 7) mice and calvarial bones from newborn (day 1) and adult (week 5) mice were removed and dissected free of tissue. For the study of extraskeletal tissue distribution, the following tissues were obtained from embryonic (15 days of gestation), newborn (day 1), and adult (week 8) mice: brain, kidney, lung, heart, liver, small intestine, skin, skeletal muscle, and spleen (week 5 adult only).

Tissue specimens were fixed immediately by immersion in 4% paraformaldehyde in diethyl ester pyrocarbonate/phosphate-buffered saline and maintained overnight at 4 °C (34). Long bones obtained from the 7-day-old and 7-week-old mice were decalcified with 15% EDTA in 0.5% paraformaldehyde/phosphate-buffered saline solution (pH 8.0) for 4 and 10 days, respectively, at 4 °C. The decalcifying solution was changed daily. All tissue specimens were processed and embedded in paraffin under sterile conditions. In situ hybridization using the 713-bp mOCIL antisense and sense riboprobes was carried out as described previously (34, 35).

For immunohistochemistry, the peptide H-Cys-Met-Ala-Gln-Glu-Ala-Gln-Leu-Ala-Arg-Phe-Asp-Asn-Gln-Asp-Glu-Leu-Asn-Phe-OH, located in the extracellular domain of OCIL, was synthesized and used to immunize rabbits following standard protocols (36). The standard peroxidase-labeled streptavidin/biotin detection method was used according to the manufacturer's instructions (Dako Corp., Carpinteria, CA) with minor modifications. The dilution of the antiserum used was optimized in preliminary experiments. Incubation of tissue sections with a 1:100 dilution of the primary antiserum was carried out overnight at 4 °C in a humidified chamber. Peroxidase activity was detected with 3',3'-diaminobenzidine tetrahydrochloride (Sigma) and 0.15% H2O2. Slides were counterstained with hematoxylin, dehydrated, and mounted with a coverslip. To confirm specificity of immunostaining, the primary antiserum was substituted with preimmune rabbit serum at the same dilution.

Statistical Analysis-- Statistics were performed using Student's t test and expressed as means ± S.E.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

OCIL-- The full-length mOCIL cDNA was 1206 bp in length. The open reading frame encodes a putative 207-amino acid peptide whose structure has characteristics typical of a type II membrane protein, with a predicted 143-amino acid extracellular domain, a 21-amino acid transmembrane domain, and a 43-amino acid cytoplasmic domain. The extracellular domain has 5 cysteine residues and three predicted N-linked glycosylation sites at residues 74, 100, and 158. A myristoylation motif is also predicted in the intracellular domain (Fig. 1).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Deduced amino acid sequence of mOCIL. The deduced amino acid sequence of mOCIL is shown, segmented into the cytoplasmic, transmembrane, and extracellular domains. The extracellular domain predicts a neck region of 15 amino acids, a 113-amino acid C-type lectin motif from positions 80 to 192 featuring the carbohydrate-binding domain, and a 15-amino acid C-terminal extension. Asterisks indicate cysteine residues, and arrowheads indicate putative N-linked glycosylation sites.

Comparison of the putative protein sequences derived from rat and mouse OCIL cDNA sequences with the Swiss Protein Database indicated that the mOCIL protein sequence included a 113-amino acid C-type lectin motif from positions 80 to 192 in the mOCIL protein sequence (Fig. 1). This C-type lectin motif is similar to that of CD69, a membrane-bound lectin expressed by bone marrow hematopoietic cells and thought to be involved in monocyte differentiation (37, 38). C-type lectin motifs are also involved in cell-cell contact and lipid binding (39-41). Homologies between the putative amino acid sequences of mouse and rat OCIL and human and mouse CD69 were noted exclusively in the respective extracellular domains of the different peptides. This is shown in Fig. 2.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 2.   Structural homology of deduced amino acid sequences of the extracellular domains, including the C-type lectin motifs, of mOCIL, rat OCIL (rOCIL), human CD69 (hCD69), and murine CD69 (mCD69). Gaps (indicated by dots) have been introduced to maximize the alignments.

Effect of mOCIL Antisense Oligonucleotides on Osteoclast Formation-- Primary calvarial osteoblasts were co-cultured with mouse bone marrow cells to generate osteoclasts. After 7 days, there was a 3-5-fold increase in the number of mononucleate TRAP-positive cells in the co-cultures treated with antisense oligonucleotides for the intracellular and extracellular domains of mOCIL compared with co-cultures performed in the absence of oligonucleotides or in the presence of OCIL scrambled oligonucleotides of the same base composition as the antisense oligonucleotides (Fig. 3A). Under these experimental conditions, multinucleate osteoclasts are generally not formed unless stimulated by 1,25-dihydroxyvitamin D3 and PGE2. A small number of multinucleate osteoclasts were observed in co-cultures treated with OCIL antisense oligonucleotides for 7 days (eight ± five/well), but none were observed in control co-cultures that were unstimulated or in those treated with OCIL sense or scrambled oligonucleotides. These experiments were performed three times, and representative results are shown. When the co-cultures were stimulated with 10 nM 1,25-dihydroxyvitamin D3 and 10 nM PGE2, multinucleate TRAP-positive osteoclasts were formed after 7 days. Treatment with 5 µM OCIL antisense oligonucleotide complementary to sequences of the extracellular domain resulted in a 7-fold increase in the number of multinucleate osteoclasts (Fig. 3B). Both mononuclear and multinucleate TRAP-positive cells were further characterized as osteoclasts by the presence of calcitonin receptors demonstrated by immunostaining, using a rabbit polyclonal antibody specific for the C-terminal intracellular domain of the mouse and rat Cla calcitonin receptor (30) (data not shown). Co-cultures treated with sense or scrambled oligonucleotides did not alter osteoclast formation, and osteoclast numbers were equivalent to similar co-cultures in which oligonucleotides were not added.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of mOCIL antisense oligonucleotides on osteoclast formation. A, murine bone marrow cells and primary calvarial osteoblasts were co-cultured for 7 days as described under "Experimental Procedures." Antisense oligonucleotide for the intracellular (dotted bar) or extracellular (hatched bar) domain of OCIL was added on days 0 and 3. Scrambled oligonucleotides with the same base composition as the antisense oligonucleotides were used as controls (C, white bar) for these experiments. At the end of the incubation period, TRAP-positive mononuclear cells (TRAP+ Mono) were counted. B, murine bone marrow cells and primary calvarial osteoblasts were co-cultured for 7 days in the presence of 10 nM 1,25-dihydroxyvitamin D3 (1,25 (OH)2D3) and 10 nM PGE2. Multinucleate TRAP-positive osteoclasts (TRAP+ MNC) were formed after 7 days. Mononucleate and multinucleate TRAP-positive cells express calcitonin receptors (data not shown). Data are representative of experiments performed three times. Bars represent means ± S.E. (n = 3 for each treatment). *, p < 0.001 versus control. A/S, antisense.

Effect of Recombinant mOCIL on Osteoclast Formation-- The increase in osteoclast formation when OCIL expression was inhibited by antisense oligonucleotides suggested that OCIL acts to inhibit osteoclast formation. This was tested by assessing osteoclast formation in the presence of the extracellular domain of mOCIL expressed as a soluble recombinant protein.

The effect of MBP-OCIL fusion protein on osteoclast formation by adherent adult mouse spleen cells treated with 50 ng/ml soluble RANKL and 25 ng/ml M-CSF for 7 days is shown in Fig. 4. Using this osteoclast generation system, potential effects of OCIL on stromal cells were eliminated, and since the cells were adherent cells (monocytes and macrophages), potential effects of OCIL on lymphocytic cells were also eliminated. Any effect of MBP on osteoclast formation was determined by the addition of MBP vector control alone. MBP-OCIL fusion protein dose-dependently inhibited the formation of osteoclasts, but MBP alone did not affect osteoclast formation.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of recombinant mOCIL on osteoclast formation. Adherent adult murine spleen cultures were treated with soluble RANKL (50 ng/ml) and M-CSF (25 ng/ml) for 7 days in the presence of increasing concentrations of MBP-OCIL fusion protein (black bars) or MBP vector control alone (hatched bars). The white bar (C, control) represents wells to which no MBP or MBP-OCIL was added. TRAP-positive multinucleate osteoclasts (TRAP+ MNC) were counted at the end of the incubation period. Data are representative of three independent experiments. Bars represent means ± S.E. (n = 3 for each treatment). *, p < 0.001 versus MBP alone.

Time Course of Effects of Recombinant mOCIL on Osteoclast Formation-- In vitro osteoclast formation can be divided into two distinct phases: proliferation (days 0-3) and differentiation (days 4-7) (42). The effects of MBP-OCIL fusion protein on the two phases of osteoclast development were examined with adult murine adherent spleen cells. MBP-OCIL fusion protein was effective in inhibiting osteoclast formation predominantly during the proliferative phase (days 0-3), with a smaller effect (70% inhibition) during the differentiation phase (days 4-7) (Fig. 5).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Time course of effects of recombinant mOCIL on osteoclast formation. Adherent adult murine spleen cultures were treated with soluble RANKL (50 ng/ml) and M-CSF (25 ng/ml) for 7 days. In A, the control (white bar) is compared with 500 ng/ml MBP alone (hatched bar) and 500 ng/ml MBP-OCIL fusion protein (black bar). Increasing concentrations of MBP-OCIL fusion protein (black bars) were added to the cultures, either during the proliferative phase (B; days 0-3) or the differentiation phase (C; days 4-7). Data are representative of three independent experiments. TRAP+ MNC, TRAP-positive multinucleate osteoclasts.

Expression of OCIL and OPG mRNAs during Osteoclast Formation in Mouse Bone Marrow Culture-- In this system, multinucleate osteoclast formation was observed after day 5 and was associated with an increase in expression of mRNA for the IL-11alpha receptor as well as the calcitonin receptor (43). OCIL mRNA was constitutively expressed in fresh bone marrow cells. Upon stimulation by 1,25-dihydroxyvitamin D3, a time-dependent decrease in OCIL mRNA relative to GAPDH mRNA occurred. By day 3, OCIL mRNA was 13% of control levels, decreasing even further by day 8. Like OCIL, OPG mRNA was constitutively expressed in fresh bone marrow cells. However, unlike OCIL, OPG mRNA expression increased 2-fold by day 4 in cultures treated with 1,25-dihydroxyvitamin D3; and by day 8, it had increased 4-fold (Fig. 6).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 6.   Expression of OCIL and OPG mRNAs during osteoclast formation in murine bone marrow culture. Murine bone marrow cells were cultured for 10 days in the presence of 10 nM 1,25-dihydroxyvitamin D3. Total RNA was isolated at each 24-h time point. Reverse transcriptase-PCR was carried out to determine the relative expression of OCIL, OPG, and GAPDH mRNAs as described under "Experimental Procedures." The OCIL/GAPDH ratio is plotted against time as percent control levels (open circle ), and the OPG/GAPDH ratio is plotted against time as -fold induction (black-triangle). CTR+, calcitonin receptor; TRAP+ MNC, TRAP-positive multinucleate osteoclasts.

Regulation of OCIL mRNA Expression in Rat Osteoblasts-- OCIL mRNA levels were examined by Northern blot analyses in primary mouse calvarial osteoblast cells and the rat osteoblast-like cell line UMR 106 following treatment with osteotropic factors for 24 h (Fig. 7). OCIL mRNA expression was up-regulated by IL-1alpha , IL-11, and 1,25-dihydroxyvitamin D3 in primary mouse calvarial cells and by retinoic acid as well as parathyroid hormone-(1-34) in UMR 106 cells.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 7.   Northern blot analyses of OCIL mRNA expression in osteoblasts. Primary mouse calvarial osteoblast cells and rat osteoblast-like cells (UMR 106) were treated in culture for 24 h with osteotropic factors at the concentrations listed. Total RNA was isolated and probed for the expression of OCIL mRNA with a digoxigenin-labeled mOCIL riboprobe. Relative mRNA levels were normalized for loading variability by comparison with 18 S rRNA levels in the same filters. The OCIL/18 S RNA ratios, normalized to control levels (1.0), are indicated below the Northern blots. Dex, dexamethasone; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; RA, retinoic acid; PTH, parathyroid hormone.

Tissue Distribution of OCIL mRNA in Adult Mouse-- Total RNA was extracted from adult (week 7) mice to determine the expression of OCIL mRNA in extraskeletal tissues by Northern blot analysis. OCIL mRNA was expressed by all tissues examined, with the highest expression in kidney, liver, gut, heart, and skeletal muscle (Fig. 8).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 8.   Tissue distribution of mOCIL. Tissues obtained from 7-week-old adult mice were subjected to Northern blot analysis using a digoxigenin-labeled mOCIL riboprobe as described under "Experimental Procedures." To ensure equal starting quantities of RNA in each sample, relative mRNA levels were normalized for loading variability by comparison with 18 S rRNA levels in the same filters. S. Muscle, skeletal muscle.

In Situ Hybridization and Immunohistochemistry-- Skeletal and extraskeletal tissues were obtained from C57BL/6J male mice to study the spatial distribution of OCIL mRNA and protein by in situ hybridization and immunohistochemistry, respectively. Long bones from the femurs and tibiae were obtained from embryonic, newborn, and adult mice, and calvarial bones were obtained from newborn and adult mice. In long bones, immunohistochemistry showed strong expression of OCIL protein in osteoblasts, chondrocytes in the growth plate, and skeletal muscle overlying the bone (Fig. 9A). In situ hybridization similarly showed strong expression of OCIL mRNA in osteoblasts (Fig. 9C).


View larger version (174K):
[in this window]
[in a new window]
 
Fig. 9.   Immunohistochemistry and in situ hybridization for mOCIL in mouse long bone. Immunohistochemistry (A and B) and in situ hybridization (C and D) were carried out on a section of long bone from neonatal (day 1) mouse as described under "Experimental Procedures." A, OCIL protein expression was observed in proliferating chondrocytes (PC), hypertrophic chondrocytes (HC), and overlying skeletal muscle (SM). B, shown is a nonimmune negative control of long bone. C, OCIL mRNA expression was demonstrated in osteoblasts as indicated by the arrowheads. D, shown is a RNase-treated section of bone included as a negative control. Original magnification × 50 (A and B) and × 200 (C and D).

For the study of extraskeletal tissue distribution, the following tissues were obtained from embryonic (15 days of gestation), newborn (day 1), and adult (week 8) mice: brain, kidney, lung, heart, liver, small intestine, skin, skeletal muscle, and spleen (week 5 adult only). The results of in situ hybridization and immunohistochemistry for OCIL expression are tabulated in Table I.

                              
View this table:
[in this window]
[in a new window]
 
Table I
In situ hybridization and immunohistochemistry for OCIL mRNA and protein, respectively, in skeletal and extraskeletal tissues from embryonic (day 15), newborn (day 1), and adult (weeks 5-8) mice
+, weak signal/staining; ++, moderate signal/staining; +++, strong signal/staining; -, absence of or negligible signal/staining; NA, not applicable; ND, not determined; mk, megakaryoblast of fetal liver; ISH, in situ hybridization; IHC, immunohistochemistry.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We report the cloning and characterization of an inhibitor of osteoclast formation (mOCIL) that belongs to the C-type lectin family. The structure of mOCIL is reminiscent of a type II transmembrane protein, with a carboxyl-terminal extracellular domain and a short amino-terminal cytoplasmic domain.

Lectins are nonenzymatic sugar-binding proteins that bind with considerable specificity to complex carbohydrate structures found on cell surfaces and in the extracellular matrix and secreted glycoproteins. They are involved in numerous cellular processes such as host-pathogen interactions, targeting of proteins within cells, and cell-cell interactions (40, 44). The calcium-dependent (C-type) lectin family includes cell adhesion molecules like selectins, which target leukocytes to lymphoid tissues and sites of inflammation (45, 46); mannose-binding proteins that function in antibody-independent host defense against pathogens (47, 48); and lecticans, a family of chondroitin sulfate proteoglycans including aggrecan, versican, neurocan, and brevican (49, 50). These proteins contain a C-type carbohydrate recognition domain attached to other domains responsible for the physiological functions of the molecule (51). Protein sequences containing C-type lectin domains are classified into seven different categories according to sequence homology and/or the overall modular architecture of the protein (52). The C-type lectin domain of mOCIL has a 36% homology to the C-lectin domain of human CD69. CD69 is the earliest leukocyte activation antigen and is expressed mainly by activated T, B, and natural killer cells. Studies in mice deficient in CD69 through targeted gene deletion suggested that CD69 plays a role in B cell development, with otherwise normal hematopoietic cell development as well as normal T cell subpopulations and functions (53). CD69 belongs to the group V category of C-type lectins, which includes natural killer dimeric cell-surface receptors CD94/NKG2, Ly-49, and NKR-P1 (48). There is little information available regarding the structure of these receptors, how they recognize their ligands, and how they form dimers.

Recombinant OCIL inhibited osteoclast formation predominantly in the proliferative phase of osteoclastogenesis, with a smaller effect during the differentiation phase. Osteoclast inhibitors such as IL-18 and GM-CSF (21) elicit their actions only during the proliferative phase of osteoclast formation, whereas legumain appears to block the later stages of osteoclast formation (22). We assessed OCIL action with adherent spleen cells to eliminate the effects of lymphocytes because IL-18 inhibits osteoclast formation via the production of GM-CSF by T cells, suggesting that the immune system may have a regulatory role in osteoclastogenesis. Identical results were obtained with T cell-depleted spleen cells (data not shown), thus suggesting that OCIL acts on osteoclast precursors independently of T cells and other lymphocytes.

Osteoblasts express RANKL and OPG as well as OCIL. Like RANKL, OCIL is a transmembrane protein that may be dependent on cell-cell interactions for its effects. Our results suggest that OCIL is capable of acting independently in regulating osteoclast formation, although cooperativity with OPG cannot be excluded. The ability of OCIL to act independently of OPG was demonstrated with adherent spleen cultures treated with RANKL and M-CSF. Such cultures lack osteoblasts; and as a consequence, OPG levels were very low (data not shown). In the mouse bone marrow culture, OCIL and OPG were constitutively expressed during the proliferative phase (days 0-4), permitting both to act in the early phase of osteoclast formation to inhibit osteoclast formation. In the later phase of osteoclast formation (days 5-8), OCIL mRNA expression was substantially suppressed, enabling the formation of multinucleate osteoclasts. In contrast, OPG mRNA not only was maintained, but was slightly increased during this phase of osteoclast formation. Although this would appear to be contrary to the actions of OPG in osteoclast formation, we hypothesize that during this later phase, OPG may be acting to inhibit the resorptive action of mature osteoclasts (19). The marked down-regulation of OCIL mRNA expression during the later phase implies that OCIL does not share this secondary function with OPG, highlighting a major difference in action between these two molecules.

The regulation of OCIL mRNA expression was also different from that of OPG. OCIL mRNA expression was increased by a variety of osteotropic factors such as retinoic acid, 1,25-dihydroxyvitamin D3, parathyroid hormone, IL-1beta , and IL-11. Similar osteotropic factors up-regulate RANKL mRNA expression (7, 12). In contrast, OPG mRNA expression is decreased by 1,25-dihydroxyvitamin D3, glucocorticoids, and PGE2 (11, 54, 55). Unlike the osteoclast inhibitors IL-18, GM-CSF, interferon-gamma , IL-4, and IL-10 (20), which are largely refractile to regulation by osteotropic agents, or the case with OPG, whose regulation opposes that of RANKL, regulation of OCIL and RANKL appears concordant, suggesting that OCIL may be a tonic inhibitor of the actions of RANKL under physiological conditions in bone. Under pathological conditions of increased bone turnover, in which osteoclast formation is increased through the actions of cytokines, the concurrent up-regulation of OCIL might act as a self-regulatory mechanism to limit osteoclast formation.

One of the more intriguing aspects of recent knowledge on RANKL and OPG has been the demonstration that both molecules are widely distributed in tissues other than bone, thus raising questions about their possible functions in extraskeletal tissues. Apart from bone, RANKL is expressed in lymphoid tissues, heart, skeletal muscle, lung, stomach, placenta, and thyroid tissue (5-8, 60) and has been shown to play an important role in the immune response (57) as well as the formation of lobulo-alveolar mammary structures during pregnancy (56). OPG is even more widely distributed than RANKL, having been detected in lung, heart, kidney, liver, gastrointestinal system, skin, brain, spinal cord, endothelial cells, aortic smooth muscle cells, dendritic and B lymphocytic cell lines, thyroid, and bone (16, 18, 58, 59). OCIL expression was found to be very similar to our previously described distribution for RANKL (60), being present also in brain, heart, skeletal muscle, skin, lung, and kidney, and the expression of OCIL in these tissues was maintained in newborn as well as adult tissues. The function of OCIL in tissues other than bone is unknown. The widespread distribution of RANKL, OPG, and OCIL suggests that each molecule probably has a multifunctional role with the possibility of different effects depending on tissue-specific microenvironments.

Recent discoveries of RANKL and OPG as promoter and inhibitor, respectively, of osteoclast formation highlight the importance of local control in this process. Studies showing that the induction of osteoclastogenesis is dependent upon the relative abundance of RANKL compared with the levels of OPG (7, 11, 12, 54, 55, 61) have led to the suggestion that RANKL and OPG may be the final two effectors determining osteoclast formation (62). Nevertheless, the results presented in this study provide good evidence that OCIL, in conjunction with RANKL, may also play an important role in the regulation of osteoclast formation. The proximity of OCIL to RANKL on the osteoblast cell membrane, together with in vitro evidence that OCIL inhibits RANKL- and M-CSF-induced osteoclast formation, is strongly suggestive of an interaction between these molecules in skeleton and perhaps in other tissues as well.

    ACKNOWLEDGEMENTS

We are grateful to Drs. T. J. Martin and M. Parker for constructive comments and to Dr. M. Ikegame for providing access to RNA from mouse marrow cultures.

    FOOTNOTES

* This work was supported by Program Grant 003211 (to H. Z., V. K., J. M. W. Q., M. T. G., and K. W. N.) from the National Health and Medical Research Council of Australia. Portions of this work were presented at the 21st Annual Meeting of the American Society of Bone and Mineral Research, September 30 to October 4, 1999, St. Louis, MO.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF321552 and AF321553.

Dagger To whom correspondence should be addressed. Tel.: 613-9288-2574; Fax: 613-9288-2581; E-mail: k.ng@medicine.unimelb.edu.au.

Published, JBC Papers in Press, February 13, 2001, DOI 10.1074/jbc.M011554200

    ABBREVIATIONS

The abbreviations used are: OPG, osteoprotegerin; M-CSF, macrophage colony-stimulating factor; GM-CSF, granulocyte/macrophage colony-stimulating factor; PGE2, prostaglandin E2; IL, interleukin; OCIL, osteoclast inhibitory lectin; mOCIL, murine OCIL; PCR, polymerase chain reaction; bp, base pair(s); TRAP, tartrate-resistant acid phosphatase; MBP, maltose-binding protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Martin, T. J., Ng, K. W., and Suda, T. (1989) Endocrinol. Metab. Clin. North Am. 18, 833-858[Medline] [Order article via Infotrieve]
2. Suda, T., Takahashi, N., and Martin, T. J. (1992) Endocr. Rev. 13, 66-80[Medline] [Order article via Infotrieve]
3. Suda, T., Takahashi, N., and Martin, T. J. (1995) in Endocrine Reviews, Monographs (Bikle, D. D. , and Negro-vilar, A., eds), Vol. 4 , pp. 266-270, Endocrine Society, Bethesda, MD
4. Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H. L., Elliott, G., Kelley, M. J., Sarosi, I., Wang, L., Xia, X. Z., Elliott, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M. B., and Boyle, W. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3540-3545[Abstract/Free Full Text]
5. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., and Galibert, L. (1997) Nature 390, 175-179[CrossRef][Medline] [Order article via Infotrieve]
6. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., III, Frankel, W. N., Lee, S. Y., and Choi, Y. (1997) J. Biol. Chem. 272, 25190-25194[Abstract/Free Full Text]
7. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3597-3602[Abstract/Free Full Text]
8. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. (1998) Cell 93, 165-176[Medline] [Order article via Infotrieve]
9. Takahashi, N., Udagawa, N., and Suda, T. (1999) Biochem. Biophys. Res. Commun. 256, 449-455[CrossRef][Medline] [Order article via Infotrieve]
10. Quinn, J. M., Elliott, J., Gillespie, M. T., and Martin, T. J. (1998) Endocrinology 139, 4424-4427[Abstract/Free Full Text]
11. Horwood, N. J., Elliott, J., Martin, T. J., and Gillespie, M. T. (1998) Endocrinology 139, 4743-4746[Abstract/Free Full Text]
12. Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., and Khosla, S. (1999) Bone (Elmsford) 25, 255-259[CrossRef][Medline] [Order article via Infotrieve]
13. Burgess, T. L., Qian, Y., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., Hu, S., and Lacey, D. L. (1999) J. Cell Biol. 145, 527-538[Abstract/Free Full Text]
14. Fuller, K., Wong, B., Fox, S., Choi, Y., and Chambers, T. J. (1998) J. Exp. Med. 188, 997-1001[Abstract/Free Full Text]
15. Udagawa, N., Takahashi, N., Jimi, E., Matsuzaki, K., Tsurukai, T., Itoh, K., Nakagawa, N., Yasuda, H., Goto, M., Tsuda, E., Higashio, K., Gillespie, M. T., Martin, T. J., and Suda, T. (1999) Bone (Elmsford) 25, 517-523[CrossRef][Medline] [Order article via Infotrieve]
16. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., and Boyle, W. J. (1997) Cell 89, 309-319[Medline] [Order article via Infotrieve]
17. Tsukii, K., Shima, N., Mochizuki, S., Yamaguchi, K., Kinosaki, M., Yano, K., Shibata, O., Udagawa, N., Yasuda, H., Suda, T., and Higashio, K. (1998) Biochem. Biophys. Res. Commun. 246, 337-341[CrossRef][Medline] [Order article via Infotrieve]
18. Kwon, B. S., Wang, S., Udagawa, N., Haridas, V., Lee, Z. H., Kim, K. K., Oh, K. O., Greene, J., Li, Y., Su, J., Gentz, R., Aggarwal, B. B., and Ni, J. (1998) FASEB J. 12, 845-854[Abstract/Free Full Text]
19. Hakeda, Y., Kobayashi, Y., Yamaguchi, K., Yasuda, H., Tsuda, E., Higashio, K., Miyata, T., and Kumegawa, M. (1998) Biochem. Biophys. Res. Commun. 251, 796-801[CrossRef][Medline] [Order article via Infotrieve]
20. Martin, T. J., Romas, E., and Gillespie, M. T. (1998) Crit. Rev. Eukaryotic Gene Expression 8, 107-123[Medline] [Order article via Infotrieve]
21. Horwood, N. J., Udagawa, N., Elliott, J., Grail, D., Okamura, H., Kurimoto, M., Dunn, A. R., Martin, T., and Gillespie, M. T. (1998) J. Clin. Invest. 101, 595-603[Abstract/Free Full Text]
22. Choi, S. J., Reddy, S. V., Devlin, R. D., Menaa, C., Chung, H., Boyce, B. F., and Roodman, G. D. (1999) J. Biol. Chem. 274, 27747-27753[Abstract/Free Full Text]
23. Chen, J. M., Dando, P. M., Rawlings, N. D., Brown, M. A., Young, N. E., Stevens, R. A., Hewitt, E., Watts, C., and Barrett, A. J. (1997) J. Biol. Chem. 272, 8090-8098[Abstract/Free Full Text]
24. Choi, S. J., Devlin, R. D., Menaa, C., Chung, H., Roodman, G. D., and Reddy, S. V. (1998) J. Clin. Invest. 102, 1360-1368[Abstract/Free Full Text]
25. Ng, K. W., Gummer, P. R., Michelangeli, V. P., Bateman, J. F., Mascara, T., Cole, W. G., and Martin, T. J. (1988) J. Bone Miner. Res. 3, 53-61[Medline] [Order article via Infotrieve]
26. Zhou, H., Hammonds, R. G. J., Findlay, D. M., Fuller, P. J., Martin, T. J., and Ng, K. W. (1991) J. Bone Miner. Res. 6, 767-777[Medline] [Order article via Infotrieve]
27. Traianedes, K., Findlay, D. M., Martin, T. J., and Gillespie, M. T. (1995) J. Biol. Chem. 270, 20891-20894[Abstract/Free Full Text]
28. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[CrossRef][Medline] [Order article via Infotrieve]
29. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., and Suda, T. (1988) Endocrinology 123, 2600-2602[Abstract]
30. Quinn, J. M., Morfis, M., Lam, M. H., Elliott, J., Kartsogiannis, V., Williams, E. D., Gillespie, M. T., Martin, T. J., and Sexton, P. M. (1999) Bone (Elmsford) 25, 1-8[CrossRef][Medline] [Order article via Infotrieve]
31. Hu, Y. S., Zhou, H., Kartsogiannis, V., Eisman, J. A., Martin, T. J., and Ng, K. W. (1998) Mol. Endocrinol. 12, 1721-1732[Abstract/Free Full Text]
32. Ikegame, M., Rakopoulos, M., Zhou, H., Houssami, S., Martin, T. J., Moselye, J. M., and Findlay, D. M. (1995) J. Bone Miner. Res. 10, 59-65[Medline] [Order article via Infotrieve]
33. Zhou, H., Manji, S. S., Findlay, D. M., Martin, T. J., Heath, J. K., and Ng, K. W. (1994) J. Biol. Chem. 269, 22433-22439[Abstract/Free Full Text]
34. Kartsogiannis, V., Moseley, J., McKelvie, B., Chou, S. T., Hards, D. K., Ng, K. W., Martin, T. J., and Zhou, H. (1997) Bone (Elmsford) 21, 385-391[CrossRef][Medline] [Order article via Infotrieve]
35. Kartsogiannis, V., Udagawa, N., Ng, K. W., Martin, T. J., Moseley, J. M., and Zhou, H. (1998) Bone (Elmsford) 22, 189-194[CrossRef][Medline] [Order article via Infotrieve]
36. Danks, J. A., Ebeling, P. R., Hayman, J., Chou, S. T., Moseley, J. M., Dunlop, J., Kemp, B. E., and Martin, T. J. (1989) J. Bone Miner. Res. 4, 273-278[Medline] [Order article via Infotrieve]
37. Lopezcabrera, M., Santis, A. G., Fernandezruiz, E., Blacher, R., Esch, F., Sanchezmateos, P., and Sanchezmadrid, F. (1993) J. Exp. Med. 178, 537-547[Abstract]
38. Marzio, R., Jirillo, E., Ransijn, A., Mauel, J., and Corradin, S. B. (1997) J. Leukocyte Biol. 62, 349-355[Abstract]
39. Sharon, N., and Lis, H. (1995) Essays Biochem. 30, 59-75[Medline] [Order article via Infotrieve]
40. Gabius, H. J. (1997) Eur. J. Biochem. 243, 543-576[Abstract]
41. Kieda, C. (1998) Adv. Exp. Med. Biol. 435, 75-82[Medline] [Order article via Infotrieve]
42. Biskobing, D. M., Fan, X., and Rubin, J. (1995) J. Bone Miner. Res. 10, 1025-1032[Medline] [Order article via Infotrieve]
43. Romas, E., Udagawa, N., Zhou, H., T., T., Saito, M., Taga, T., Hilton, D. J., Suda, T., Ng, K. W., and Martin, T. J. (1996) J. Exp. Med. 183, 2581-2591[Abstract]
44. Drickamer, K., and Taylor, M. E. (1993) Annu. Rev. Cell Biol. 9, 237-264[CrossRef]
45. Cummings, R. D., and Smith, D. F. (1992) Bioessays 14, 849-856[Medline] [Order article via Infotrieve]
46. Lasky, L. A. (1992) Science 258, 964-969[Medline] [Order article via Infotrieve]
47. Taylor, M. E., Conary, J. T., Lennartz, M. R., Stahl, P. D., and Drickamer, K. (1990) J. Biol. Chem. 265, 12156-12162[Abstract/Free Full Text]
48. Weis, W. I., Kahn, R., Fourme, R., Drickamer, K., and Hendrickson, W. A. (1991) Science 254, 1608-1615[Medline] [Order article via Infotrieve]
49. Aspberg, A., Miura, R., Bourdoulous, S., Shimonaka, M., Heinegard, D., Schachner, M., Ruoslahti, E., and Yamaguchi, Y. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10116-10121[Abstract/Free Full Text]
50. Miura, R., Aspberg, A., Ethell, I. M., Hagihara, K., Schnaar, R. L., Ruoslahti, E., and Yamaguchi, Y. (1999) J. Biol. Chem. 274, 11431-11438[Abstract/Free Full Text]
51. Drickamer, K. (1988) J. Biol. Chem. 263, 9557-9560[Free Full Text]
52. Drickamer, K. (1993) Curr. Opin. Struct. Biol. 3, 393-400
53. Lauzurica, P., Sancho, D., Torres, M., Albella, B., Marazuela, M., Merino, T., Bueren, J. A., Martinez, A. C., and Sanchez-Madrid, F. (2000) Blood 95, 2312-2320[Abstract/Free Full Text]
54. Brandstrom, H., Jonsson, K. B., Ohlsson, C., Vidal, O., Ljunghall, S., and Ljunggren, O. (1998) Biochem. Biophys. Res. Commun. 247, 338-341[CrossRef][Medline] [Order article via Infotrieve]
55. Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., and Khosla, S. (1999) Endocrinology 140, 4382-4389[Abstract/Free Full Text]
56. Fata, J. E., Kong, Y. Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., Boyle, W. J., Khokha, R., and Penninger, J. M. (2000) Cell 103, 41-50[Medline] [Order article via Infotrieve]
57. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., and Penninger, J. M. (1999) Nature 397, 315-323[CrossRef][Medline] [Order article via Infotrieve]
58. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T., and Higashio, K. (1998) Endocrinology 139, 1329-1337[Abstract/Free Full Text]
59. Tan, K. B., Harrop, J., Reddy, M., Young, P., Terrett, J., Emery, J., Moore, G., and Truneh, A. (1997) Gene (Amst.) 204, 35-46[CrossRef][Medline] [Order article via Infotrieve]
60. Kartsogiannis, V., Zhou, H., Horwood, N. J., Thomas, R. J., Hards, D. K., Quinn, J. M., Niforas, P., Ng, K. W., Martin, T. J., and Gillespie, M. T. (1999) Bone (Elmsford) 25, 525-534[CrossRef][Medline] [Order article via Infotrieve]
61. Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., and Khosla, S. (1998) Biochem. Biophys. Res. Commun. 250, 776-781[CrossRef][Medline] [Order article via Infotrieve]
62. Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., and Riggs, B. L. (2000) J. Bone Miner. Res. 15, 2-12[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.